These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11709366)

  • 1. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
    Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
    Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
    Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
    Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
    J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
    Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
    Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
    Goujard C; Vincent I; Meynard JL; Choudet N; Bollens D; Rousseau C; Demarles D; Gillotin C; Bidault R; Taburet AM
    Antimicrob Agents Chemother; 2003 Jan; 47(1):118-23. PubMed ID: 12499178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
    Washington CB; Flexner C; Sheiner LB; Rosenkranz SL; Segal Y; Aberg JA; Blaschke TF;
    Clin Pharmacol Ther; 2003 May; 73(5):406-16. PubMed ID: 12732841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing.
    Sadler BM; Gillotin C; Lou Y; Stein DS
    Antimicrob Agents Chemother; 2001 Jan; 45(1):30-7. PubMed ID: 11120940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
    Gao W; Kageyama M; Inoue Y; Tadano J; Fukumoto K; Fukushima K; Yamasaki D; Nishimura A; Yoshikawa Y; Shibata N; Takada K
    Biol Pharm Bull; 2003 Feb; 26(2):199-204. PubMed ID: 12576680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.
    Brophy DF; Israel DS; Pastor A; Gillotin C; Chittick GE; Symonds WT; Lou Y; Sadler BM; Polk RE
    Antimicrob Agents Chemother; 2000 Apr; 44(4):978-84. PubMed ID: 10722500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
    Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR
    J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
    Ofotokun I; Acosta EP; Lennox JL; Pan Y; Easley KA
    Pharmacotherapy; 2008 Jan; 28(1):74-81. PubMed ID: 18154477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
    Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
    Kuschak D; Mauss S; Schmutz G; Gantke B
    Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir.
    Corbett AH; Eron JJ; Fiscus SA; Rezk NL; Kashuba AD
    J Acquir Immune Defic Syndr; 2004 Aug; 36(4):921-8. PubMed ID: 15220698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
    Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
    J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.
    Veronese L; Rautaureau J; Sadler BM; Gillotin C; Petite JP; Pillegand B; Delvaux M; Masliah C; Fosse S; Lou Y; Stein DS
    Antimicrob Agents Chemother; 2000 Apr; 44(4):821-6. PubMed ID: 10722476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
    van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.